Walnut Creek, CA, USA, January 31, 2022 – Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough–to–treat cancers, continues to grow its Neuro-Oncology Advisory

Vivacitas will be attending and presenting a poster on its lead asset, AR-67 at the 3rd Annual Glioblastoma Drug Development Summit.

Vivacitas proudly announces that Dr. Erkut Borazanci, MD, has joined its Pancreatic Medical Advisory Board.

Vivacitas announces that its CEO, Mark Suseck, will present at the 2022 Biotech Showcase Conference, an investors event focused on biotechnology innovation that will be held virtually next January 10-12 and 17-19

Vivacitas Oncology, Inc. is pleased to announce that Dr. Jai Grewal, MD, has agreed to become a new member of their distinguished Neuro-Oncology Advisory Board. Dr. Grewal will be joining Dr. Andrew Lassman, MD, MS, FAAN in the company’s Scientific Advisory Board.

WALNUT CREEK, CALIFORNIA, US, December 15, 2021 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately-held oncology company focused on tough–to–treat cancers, is pleased